Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06845202 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
A Phase 1 study of Type 2 Diabetes Mellitus (T2DM) and Obese or Overweight Healthy Volunteers, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 2
- Study locations
NCT06845202: Recruiting Phase 1 study of Type 2 Diabetes Mellitus (T2DM) and Obese or Overweight Healthy Volunteers, sponsored by Alnylam Pharmaceuticals.
NCT06845202 is a Phase 1 study of Type 2 Diabetes Mellitus (T2DM) and Obese or Overweight Healthy Volunteers that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 144 participants, below the 516-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06845202, a Phase 1 study of Type 2 Diabetes Mellitus (T2DM) and Obese or Overweight Healthy Volunteers, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALN-4324
Study Locations (2)
Florida
- Clinical Trial Site - Miami
Other
- Clinical Trial Site - Mount Royal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
What NCT06845202 shows while recruiting
NCT06845202 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 516-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06845202 reports a single indexed study location in Florida, Other.
Frequently Asked Questions
What is clinical trial NCT06845202 about?
NCT06845202 is a clinical study titled "A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM". The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult over...
What is the current status of trial NCT06845202?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2025-03-03. Estimated completion is 2027-08-31.
What conditions does trial NCT06845202 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Obese or Overweight Healthy Volunteers.
What interventions are being tested in trial NCT06845202?
The interventions under investigation include: Placebo (DRUG), ALN-4324 (DRUG).
Who is sponsoring clinical trial NCT06845202?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06845202 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06845202's enrollment target sits among peer trials
144 13th of 24 higher than 12 of 24 other Type 2 Diabetes Mellitus (T2DM) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus (T2DM) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Achieving Routine Intervention and Screening for Emotional Health
RECRUITING · NA
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
CGM for Management of Type 2 Diabetes in Pregnancy
RECRUITING · NA
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI